This Month in JNM

August 1, 2019

Discussions with leaders—JNM editor in chief, Johannes Czernin, MD, conducts an interview with Hedvig Hricak on her experience as a long-time department chair and solicits her perspective on leadership, technologic innovation, and the future of nuclear medicine. Page 1038

Hot Topics—AI in nuclear cardiology: Gomez and Doukky provide perspective on the potential for artificial intelligence technologies, including machine learning, in enhancing risk prediction in nuclear cardiology. Page 1042

State of the Art—Dedicated brain PET: Catana offers a state-of-the-art overview of current PET devices specifically designed for imaging the human brain, including performance characteristics, inclusion of other modalities, and goals for future-generation instrumentation. Page 1044

18F-FET PET after brain tumor surgery: Marner and colleagues ask whether additional postoperative 18F-FET PET in children and adolescents with brain tumors can improve diagnostic accuracy for residual tumor compared with MR imaging. Page 1053

82Rb PET/CT in prostate cancer: Jochumsen and colleagues evaluate 82Rb PET/CT as a diagnostic tool for quantitative tumor blood flow imaging in prostate cancer patients and as a noninvasive biomarker for tumor aggressiveness and monitoring in nonmetastatic prostate cancer. Page 1059

Imaging biomarkers for 90Y distribution: Schobert and colleagues identify baseline imaging features in patients with liver cancer that correlate with 90Y distribution on postprocedural SPECT and predict tumor response to transarterial radioembolization. Page 1066

Intraperitoneal 211At in ovarian cancer: Hallqvist and colleagues present clinical outcomes and toxicity data in a long-term follow-up of a phase I trial with intraperitoneal α-particle therapy in epithelial ovarian cancer. Page 1073

PET/MRI repeatability in pelvic tumors: Fraum and colleagues determine the test–retest repeatability of PET/MR imaging SUV and apparent diffusion coefficient metrics in solid tumors of the pelvis and compare these results with those from PET/CT. Page 1080

Whole-body PET in pediatric lymphoma: Cerci and colleagues assess the incidence and clinical impact of lesions outside the “eyes to thighs” field of view in 18F-FDG PET/CT staging and interim scans in pediatric lymphoma patients. Page 1087

Metabolic tumor volume in lymphoma: Gallamini provides a brief road map for validation and standardization of metabolic tumor volume computation and previews a relevant article in this issue of JNM. Page 1094

Standardized MTV measurement: Barrington and Meignan report on discussions from the PET International Lymphoma and Myeloma Workshop and offer a proposal for performance of technical validation of metabolic tumor volume measurement to enable benchmark reference ranges. Page 1096

Molecular imaging of nimotuzumab ADCs: Hartimath and colleagues use small-animal SPECT/CT and ex vivo distribution studies of antibody drug conjugates with PEGylated-maytansine to provide insights for evaluation of pharmacokinetics and normal tissue toxicity to determine dosing rates. Page 1103

Healthy tissue and PCa PET tracers: Jansen and colleagues quantify uptake variability of prostate cancer tracers, including 68Ga-PSMA, 18F-DCFPyL, 18F-FCH, and 18F-FDHT, in healthy tissues and identify stable reference regions for PET interpretation. Page 1111

PSMA PET/MR in recurrent PCa after HIFU: Burger and colleagues investigate whether 68Ga-PSMA-11 can be used to localize recurrent disease with PET/MR in patients with discrepant findings after high-intensity focused ultrasound treatment for prostate cancer. Page 1118

MC1R-targeted α-particle therapy: Tafreshi and colleagues report on preclinical development and testing of a novel melanocortin 1 receptor–targeted radiopharmaceutical, 225Ac-DOTA-MC1RL, for α-particle therapy of uveal melanoma. Page 1124

Perfusion scintigraphy in PE follow-up: Marconi and colleagues look at changes in pulmonary perfusion at 4 follow-up points within 1 y in patients with pulmonary embolism and elucidate factors predictive of complete or incomplete recovery of perfusion. Page 1134

Featured Article of the Month—11β-HSD1–targeted brain imaging: Gallezot and colleagues detail the results of studies with 11C-AS2471907 PET to image 11β-hydroxysteroid dehydrogenase type 1 enzyme availability in the human brain. Page 1140

Featured Translational Science Article—M1 mAChR PET imaging in NHPs: Nabulsi and colleagues report on the synthesis and evaluation of 11C-LSN3172176, targeting the M1 muscarinic acetylcholine receptor, with PET imaging in nonhuman primates. Page 1147

18F-JNJ-64413739 P2X7 PET: Kolb and colleagues describe in vitro and in vivo preclinical studies with this 18F-labeled PET ligand for imaging the P2X7 receptor in the brain. Page 1154

18F-labeled PSMA ligands: Kuo and colleagues evaluate a series of prostate-specific membrane–targeting probes and label them with 18F in a single step for PET imaging of prostate cancer. Page 1160

GluN2B and σ1R PET: Haider and colleagues investigate the performance characteristics of the enantiomers of 11C-Me-NB1, a recently reported PET imaging probe that targets the glutamate N2B subunit of N-methyl-d-aspartate receptors. Page 1167

FcγRI binding and immuno-PET: Vivier and colleagues determine whether radioimmunoconjugates with truncated glycans exhibit altered binding to immune cells bearing Fc-γ-receptors and, in turn, improve in vivo performance on antibody-targeted PET imaging. Page 1174

Deep learning in WB ToF PET/MRI: Hwang and colleagues propose a new deep learning–based approach to provide more accurate whole-body time-of-flight PET/MRI attenuation correction than is possible with the Dixon-based 4-segment method. Page 1183